Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MARIO CASTRO

Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease

NPI
1881610004
CMS profile
176181
Location
KANSAS CITY, KS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$531,790.85

482 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 4 of 10; records 151–200 of 482 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MARIO CASTRO

NPI 1881610004 · CMS profile ID 176181

Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease

KANSAS CITY, KS

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 10; records 151–200 of 482 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1881610004?year=2019&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MARIO CASTRO, NPI 1881610004, CMS profile ID 176181. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 10; records 151–200 of 482 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1881610004?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). MARIO CASTRO, NPI 1881610004, CMS profile ID 176181. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 10; records 151–200 of 482 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1881610004?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
MARIO CASTRO, NPI 1881610004, CMS profile ID 176181, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 10; records 151–200 of 482 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1881610004?year=2019&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

482 matching records · $531,790.85 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 482 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 482.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $651.7107/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685628481 CMS
AstraZeneca Pharmaceuticals LP $76.6407/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685898703 CMS
Teva Pharmaceuticals USA, Inc. $311.2407/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697862127 CMS
Teva Pharmaceuticals USA, Inc. $42.4507/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697862153 CMS
AstraZeneca Pharmaceuticals LP $2,000.0007/15/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685170703 CMS
Regeneron Healthcare Solutions, Inc. $5,517.0007/15/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673357599 CMS
Teva Pharmaceuticals USA, Inc. $4,040.0007/15/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697862125 CMS
GlaxoSmithKline, LLC. $3,600.0007/09/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671468769 CMS
Regeneron Healthcare Solutions, Inc. $36.6307/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673357595 CMS
Regeneron Healthcare Solutions, Inc. $12.2807/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673357597 CMS
Teva Pharmaceuticals USA, Inc. $392.2307/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697862129 CMS
AstraZeneca Pharmaceuticals LP $4,300.0007/03/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685272331 CMS
AstraZeneca Pharmaceuticals LP $1,600.0007/03/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685819391 CMS
GlaxoSmithKline, LLC. $800.0007/03/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670960631 CMS
GlaxoSmithKline, LLC. $23.2007/03/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 671479285 CMS
Regeneron Healthcare Solutions, Inc. $2,758.5007/03/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673357593 CMS
AstraZeneca Pharmaceuticals LP $4,300.0007/02/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685721357 CMS
Teva Pharmaceuticals USA, Inc. $583.2107/02/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697862117 CMS
AstraZeneca Pharmaceuticals LP $1,600.0006/30/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685088105 CMS
GlaxoSmithKline, LLC. $106.3006/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670271233 CMS
GlaxoSmithKline, LLC. $1,461.7506/27/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670273068 CMS
AstraZeneca Pharmaceuticals LP $1,600.0006/26/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685433173 CMS
AstraZeneca Pharmaceuticals LP $4,300.0006/26/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686007023 CMS
Regeneron Healthcare Solutions, Inc. $3,678.0006/26/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673357589 CMS
Regeneron Healthcare Solutions, Inc. $2,758.5006/26/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673357591 CMS
AstraZeneca Pharmaceuticals LP $23.2006/25/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685198931 CMS
AstraZeneca Pharmaceuticals LP $106.7606/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685313671 CMS
AstraZeneca Pharmaceuticals LP $1,755.3906/25/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685686123 CMS
AstraZeneca Pharmaceuticals LP $14.3106/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685721289 CMS
AstraZeneca Pharmaceuticals LP $310.2406/25/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685920421 CMS
AstraZeneca Pharmaceuticals LP $33.6906/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685973327 CMS
Regeneron Healthcare Solutions, Inc. $21.9306/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673357587 CMS
Regeneron Healthcare Solutions, Inc. $10.7306/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673357575 CMS
Regeneron Healthcare Solutions, Inc. $25.0006/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673357577 CMS
Regeneron Healthcare Solutions, Inc. $30.0006/24/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673357579 CMS
Regeneron Healthcare Solutions, Inc. $178.2706/24/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673357581 CMS
Regeneron Healthcare Solutions, Inc. $947.6206/24/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673357583 CMS
Regeneron Healthcare Solutions, Inc. $1,197.0006/24/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673357585 CMS
AstraZeneca Pharmaceuticals LP $48.8706/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685259159 CMS
AstraZeneca Pharmaceuticals LP $28.5306/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685664597 CMS
AstraZeneca Pharmaceuticals LP $605.7706/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685790371 CMS
AstraZeneca Pharmaceuticals LP $2,047.0806/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685909161 CMS
Regeneron Healthcare Solutions, Inc. $602.7806/22/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673357571 CMS
Regeneron Healthcare Solutions, Inc. $125.0006/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673357573 CMS
AstraZeneca Pharmaceuticals LP $13.5406/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685169306 CMS
AstraZeneca Pharmaceuticals LP $23.2006/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685737627 CMS
AstraZeneca Pharmaceuticals LP $120.1006/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685762669 CMS
Regeneron Healthcare Solutions, Inc. $116.1606/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673357567 CMS
Regeneron Healthcare Solutions, Inc. $117.5006/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673357569 CMS
Regeneron Healthcare Solutions, Inc. $374.0606/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673357565 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $531,790.85 482
PY2020 $146,585.50 94
PY2021 $145,878.43 99
PY2022 $210,659.47 156
PY2023 $252,551.29 186
PY2024 $288,909.31 159
PY2025 $288,576.28 140

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $11,500.00 27
PY2025 Principal investigator $517,850.26 86
PY2024 Recipient $7,250.00 21
PY2024 Principal investigator $581,361.15 45
PY2023 Recipient $3,500.00 7
PY2023 Principal investigator $465,662.37 44
PY2022 Recipient $14,711.51 31
PY2022 Principal investigator $121,284.22 12
PY2021 Recipient $9,000.00 22
PY2021 Principal investigator $169,147.88 26
PY2020 Recipient $15,274.16 25
PY2020 Principal investigator $78,092.05 10
PY2019 Recipient $22,226.52 55
PY2019 Principal investigator $22,455.40 5

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

113 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $260.33 12/24/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184280258
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,586.31 12/19/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184278646
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $653.40 12/11/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046802
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $522.65 12/11/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046804
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $600.00 12/11/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046806
Principal investigator 1 SANOFI US SERVICES INC. $150.00 12/08/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Research Institute Inc Kumc Research Institute
A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226096778
Principal investigator 1 GlaxoSmithKline, LLC. $3,950.75 12/01/2025 Non-covered Recipient Entity
KUMC RESEARCH INSTITUTE INC
THE IMAGINE STUDY: A PHASE 3B OPEN LABEL, SINGLE ARM STUDY TO ASSESS T No dispute reported 06/30/2026 1192173477
Principal investigator 1 GlaxoSmithKline, LLC. $15,650.00 12/01/2025 Non-covered Recipient Entity
KUMC RESEARCH INSTITUTE INC
THE IMAGINE STUDY: A PHASE 3B OPEN LABEL, SINGLE ARM STUDY TO ASSESS T No dispute reported 06/30/2026 1192173481
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,135.92 11/27/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184266125
Recipient GENZYME CORPORATION $250.00 11/26/2025 Covered Recipient Physician Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma No dispute reported 06/30/2026 1226106704
Recipient GENZYME CORPORATION $500.00 11/26/2025 Covered Recipient Physician Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma No dispute reported 06/30/2026 1226106717
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,628.61 11/20/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046800
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $260.33 11/19/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184262643
Principal investigator 1 SANOFI US SERVICES INC. $4,550.00 11/04/2025 Non-covered Recipient Entity
University Of Kansas Medical Center Research Institute Inc Kumc Research Institute
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1226096773
Recipient GENZYME CORPORATION $1,250.00 10/27/2025 Covered Recipient Physician Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma No dispute reported 06/30/2026 1226106675
Recipient GENZYME CORPORATION $250.00 10/24/2025 Covered Recipient Physician A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma No dispute reported 06/30/2026 1226106711
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $2,821.52 10/23/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046798
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $260.33 10/17/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184251393
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $158.00 10/15/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184250313
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $158.00 10/15/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184250315
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $80.00 10/15/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184250317
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $91.00 10/15/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184250319
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $91.00 10/15/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184250321
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $80.00 10/15/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184250323
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $91.00 10/15/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184250325
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $158.00 10/15/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184250327
Recipient GENZYME CORPORATION $250.00 10/14/2025 Covered Recipient Physician Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma No dispute reported 06/30/2026 1226106669
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $522.65 10/14/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046796
Principal investigator 1 PFIZER INC. $83.44 10/03/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED MODERATETOSEVERE ASTHMA No dispute reported 06/30/2026 1228824203
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $522.65 09/25/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046794
Principal investigator 1 Galvanize Therapeutics, Inc $15,567.45 09/15/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS SCHOOL OF MEDICINE
CS006 RHEOX PIVOTAL No dispute reported 06/30/2026 1238409125
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,544.60 09/15/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184237494
Principal investigator 1 PFIZER INC. $1,750.00 09/11/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED MODERATETOSEVERE ASTHMA No dispute reported 06/30/2026 1228834728
Principal investigator 1 PFIZER INC. $21,042.00 08/22/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute Inc
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED MODERATETOSEVERE ASTHMA No dispute reported 06/30/2026 1228842740
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,519.56 08/20/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184228861
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $260.33 08/20/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184228863
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $260.33 08/20/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184228865
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,778.89 08/19/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046792
Principal investigator 1 SANOFI US SERVICES INC. $13.92 08/11/2025 Non-covered Recipient Entity
University Of Kansas Hospital
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1226108765
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $668.00 07/25/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184220124
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $99.00 07/25/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184220126
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,450.00 07/25/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184220128
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $80.00 07/25/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184220130
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,276.75 07/24/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046790
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,735.00 07/22/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046788
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $6,243.02 07/18/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046786
Principal investigator 1 SANOFI US SERVICES INC. $5,400.00 07/14/2025 Non-covered Recipient Entity
University Of Kansas Hospital
A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226108741
Principal investigator 1 AstraZeneca Pharmaceuticals LP $29,460.74 07/11/2025 Non-covered Recipient Entity
KUMC RESEARCH INSTITUTE INC
Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease COPD No dispute reported 06/30/2026 1185538320
Recipient GENZYME CORPORATION $250.00 07/11/2025 Covered Recipient Physician Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma No dispute reported 06/30/2026 1226106688
Recipient GENZYME CORPORATION $500.00 07/11/2025 Covered Recipient Physician Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma No dispute reported 06/30/2026 1226106809
Principal investigator 1 Galvanize Therapeutics, Inc $2,212.59 07/09/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS SCHOOL OF MEDICINE
CS006 RHEOX PIVOTAL No dispute reported 06/30/2026 1238409097
Principal investigator 1 SANOFI US SERVICES INC. $5,010.00 07/07/2025 Non-covered Recipient Entity
University Of Kansas Hospital
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1226108736
Principal investigator 1 PFIZER INC. $1,245.00 07/03/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED MODERATETOSEVERE ASTHMA No dispute reported 06/30/2026 1228844002
Principal investigator 1 PFIZER INC. $275.00 07/03/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER
A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED MODERATETOSEVERE ASTHMA No dispute reported 06/30/2026 1228844023
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $634.13 07/02/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184212481
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $164.21 07/02/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184212483
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,477.85 06/30/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184212167
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $770.32 06/27/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184211737
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,847.56 06/27/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184211907
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,135.92 06/27/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184211933
Principal investigator 1 SANOFI US SERVICES INC. $150.00 06/16/2025 Non-covered Recipient Entity
University Of Kansas Hospital
A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226108725
Recipient GENZYME CORPORATION $500.00 06/15/2025 Covered Recipient Physician A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma No dispute reported 06/30/2026 1226106799
Recipient GENZYME CORPORATION $250.00 06/14/2025 Covered Recipient Physician A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma No dispute reported 06/30/2026 1226106700
Recipient GENZYME CORPORATION $250.00 06/13/2025 Covered Recipient Physician Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma No dispute reported 06/30/2026 1226106696
Recipient GENZYME CORPORATION $500.00 06/13/2025 Covered Recipient Physician Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma No dispute reported 06/30/2026 1226106757
Recipient GENZYME CORPORATION $250.00 06/13/2025 Covered Recipient Physician Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma No dispute reported 06/30/2026 1226106805
Recipient GENZYME CORPORATION $500.00 06/12/2025 Covered Recipient Physician Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma No dispute reported 06/30/2026 1226106748
Recipient GENZYME CORPORATION $250.00 06/06/2025 Covered Recipient Physician Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma No dispute reported 06/30/2026 1226106773
Recipient GENZYME CORPORATION $500.00 05/20/2025 Covered Recipient Physician Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma No dispute reported 06/30/2026 1226106786
Recipient GENZYME CORPORATION $500.00 05/18/2025 Covered Recipient Physician Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma No dispute reported 06/30/2026 1226106763
Recipient GENZYME CORPORATION $250.00 05/18/2025 Covered Recipient Physician Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma No dispute reported 06/30/2026 1226106792
Recipient GENZYME CORPORATION $250.00 05/17/2025 Covered Recipient Physician Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma No dispute reported 06/30/2026 1226106681
Principal investigator 1 SANOFI US SERVICES INC. $2,385.15 05/05/2025 Non-covered Recipient Entity
University Of Kansas Hospital
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1226108706
Principal investigator 1 Galvanize Therapeutics, Inc $3,851.02 04/29/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS SCHOOL OF MEDICINE
CS006 RHEOX PIVOTAL No dispute reported 06/30/2026 1238409067
Principal investigator 1 SANOFI US SERVICES INC. $150.00 04/28/2025 Non-covered Recipient Entity
University Of Kansas Hospital
A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226108710
Principal investigator 1 SANOFI US SERVICES INC. $3,647.26 04/28/2025 Non-covered Recipient Entity
University Of Kansas Hospital
A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226108716
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,679.41 04/25/2025 Non-covered Recipient Entity
KUMC RESEARCH INSTITUTE INC
A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE) No dispute reported 06/30/2026 1185538316
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,810.43 04/25/2025 Non-covered Recipient Entity
KUMC RESEARCH INSTITUTE INC
A Phase 4 Multicenter Randomized Double blind Parallel Group Placebo controlled Study to Evaluate the Effect of Benralizumab on Structural and Lung Function Changes in Severe Eosinophilic Asthmatics (CHINOOK) No dispute reported 06/30/2026 1185538328
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,992.98 04/24/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046784
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $974.00 04/23/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184188669
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $15,650.00 04/23/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184188671
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,000.00 04/23/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184188673
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,535.00 04/23/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184188675
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,350.00 04/23/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184188677
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,750.00 04/23/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184188679
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,202.00 04/23/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184188681
Recipient GENZYME CORPORATION $500.00 04/17/2025 Covered Recipient Physician A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma No dispute reported 06/30/2026 1226106663
Recipient GENZYME CORPORATION $500.00 04/16/2025 Covered Recipient Physician A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma No dispute reported 06/30/2026 1226106779
Recipient GENZYME CORPORATION $250.00 04/15/2025 Covered Recipient Physician A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma No dispute reported 06/30/2026 1226106767
Principal investigator 1 AstraZeneca Pharmaceuticals LP $8,999.17 04/11/2025 Non-covered Recipient Entity
KUMC RESEARCH INSTITUTE INC
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab (MEDI3506) in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations No dispute reported 06/30/2026 1185538326
Principal investigator 1 SANOFI US SERVICES INC. $4,550.00 04/02/2025 Non-covered Recipient Entity
University Of Kansas Hospital
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1226108663
Principal investigator 1 SANOFI US SERVICES INC. $150.00 04/02/2025 Non-covered Recipient Entity
University Of Kansas Hospital
A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226108686
Principal investigator 1 SANOFI US SERVICES INC. $2,850.00 03/17/2025 Non-covered Recipient Entity
University Of Kansas Hospital
A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226108644
Recipient GENZYME CORPORATION $250.00 03/12/2025 Covered Recipient Physician Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma No dispute reported 06/30/2026 1226106729
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $66.75 03/06/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046782
Recipient GENZYME CORPORATION $500.00 03/01/2025 Covered Recipient Physician Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma No dispute reported 06/30/2026 1226106651
Recipient GENZYME CORPORATION $250.00 03/01/2025 Covered Recipient Physician Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma No dispute reported 06/30/2026 1226106742
Principal investigator 1 AstraZeneca Pharmaceuticals LP $31,425.34 02/28/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER CYSTIC FIBROSIS PROGRAM
A Phase 4 Multicenter Randomized Double blind Parallel Group Placebo controlled Study to Evaluate the Effect of Benralizumab on Structural and Lung Function Changes in Severe Eosinophilic Asthmatics (CHINOOK) No dispute reported 06/30/2026 1185538330
Recipient GENZYME CORPORATION $500.00 02/28/2025 Covered Recipient Physician A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma No dispute reported 06/30/2026 1226106736
Recipient GENZYME CORPORATION $250.00 02/27/2025 Covered Recipient Physician A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma No dispute reported 06/30/2026 1226106657
Principal investigator 1 SANOFI US SERVICES INC. $3,200.84 02/24/2025 Non-covered Recipient Entity
University Of Kansas Hospital
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma No dispute reported 06/30/2026 1226108670
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $204.60 02/21/2025 Non-covered Recipient Entity
University of Kansas Medical Center Research Institute, Inc.
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma No dispute reported 06/30/2026 1244046842
Principal investigator 1 Galvanize Therapeutics, Inc $34,678.06 02/18/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS SCHOOL OF MEDICINE
CS006 RHEOX PIVOTAL No dispute reported 06/30/2026 1238409019
Principal investigator 1 Galvanize Therapeutics, Inc $34,277.56 02/18/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS SCHOOL OF MEDICINE
CS006 RHEOX PIVOTAL No dispute reported 06/30/2026 1238409021
Principal investigator 1 SANOFI US SERVICES INC. $400.00 02/18/2025 Non-covered Recipient Entity
University Of Kansas Hospital
A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226108650
Principal investigator 1 AstraZeneca UK Limited $30,546.32 02/14/2025 Non-covered Recipient Entity
DUKE UNIVERSITY
A Phase III Multicentre Randomised Double blind Chronic dosing Parallel group Placebo controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease COPD with a History of COPD Exacerbations OBERON No dispute reported 06/30/2026 1185538318
Recipient GENZYME CORPORATION $1,250.00 02/10/2025 Covered Recipient Physician Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma No dispute reported 06/30/2026 1226106722
Principal investigator 1 AstraZeneca Pharmaceuticals LP $101,199.89 01/29/2025 Non-covered Recipient Entity
KUMC RESEARCH INSTITUTE INC
Levante A Phase 2b Randomised Double Blind Placebo Controlled Dose Range Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630 No dispute reported 06/30/2026 1185538322
Principal investigator 1 SANOFI US SERVICES INC. $14,605.04 01/27/2025 Non-covered Recipient Entity
University Of Kansas Hospital
A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226108656
Principal investigator 1 AstraZeneca Pharmaceuticals LP $7,326.06 01/17/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER CYSTIC FIBROSIS PROGRAM
A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE) No dispute reported 06/30/2026 1185538314
Principal investigator 1 AstraZeneca Pharmaceuticals LP $36,455.32 01/15/2025 Non-covered Recipient Entity
UNIVERSITY OF KANSAS MEDICAL CENTER CYSTIC FIBROSIS PROGRAM
A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab (MEDI3506) in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations No dispute reported 06/30/2026 1185538312
Principal investigator 1 SANOFI US SERVICES INC. $5,400.00 01/13/2025 Non-covered Recipient Entity
University Of Kansas Hospital
A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226108693
Principal investigator 1 SANOFI US SERVICES INC. $5,400.00 01/06/2025 Non-covered Recipient Entity
University Of Kansas Hospital
A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD) No dispute reported 06/30/2026 1226108700